SUMMARY A case is reported of a patient who presented with symptomatic hypoglycaemia and who had three pancreatic tumours resected over the ensuing eight years. Immunocytochemistry demonstrated two of these to be insulinomas and the third to be a glucagonoma. In addition metastatic spread of cells positive for glucagon had occurred to a lymph node and multiple nodules staining positively for glucagon were present in the remainder of the pancreas.
Pancreatic endocrine tumours are uncommon but of great interest because of the variety of clinical syndromes which they produce. Sensitive immunocytochemical studies have shown that many of these tumours are composed of several cell types and are multihormonal.4 5 0
Transformation from one syndrome to another has been reported9 and presumed to be due to change in type of the dominant cell in a mixed tumour. We report a case of recurrent insulinoma syndrome with metastatic glucagonoma, shown by immunocytochemistry to be due to the coexistence of insulinoma and glucagonoma. The of Stemberger et al,2 after treatment with trypsin,3 using antisera to insulin, glucagon, and somatostatin. The antisera were used at the following dilutions: guinea pig anti-insulin (Immuno-nuclear Corp., PO Box 285, Stillwater, Minnesota, USA) 1/500; rabbit antiglucagon (Mercia Brocades, Brocades House, Pyrford Road, West Byfleet, Surrey) 1/500; rabbit antisomatostatin (Immunonuclear Corp., PO Box 285, Stillwater, Minnesota, USA) 1/800. The second and third stages were performed using sheep antirabbit (RIA UK, 3 Manor Place, Athenaeum Street, Sunderland) and rabbit PAP complex (Mercia Brocades). Appropriate controls were performed, using the specific antibodies after prior absorption with an excess of the corresponding antigen as a first layer, non-immune serum as first layer, and by omission of 3,3'diaminobenzidine tetrahydrochloride from the incubation medium for the peroxidase reaction.
PATHOLOGICAL FINDINGS
The findings are described separately for the three tumours, identified by the year of removal. (Fig. 2) . 1982 This specimen consisted of pylorus, duodenum, and the head of the pancreas. Within the head of the pancreas and extending to the anterior border there was a firm congested clearly defined nodule 2 cm diameter. The pancreatic tissue was otherwise unremarkable macroscopically. Several small peripancreatic lymph nodes were identified. Micros- copy of the tumour showed identical appearances to the previous specimen apart from the absence of a clearly defined capsule (Fig. 3) . Silver-positive granules were again demonstrable and aldehyde fuchsin and lead haematoxylin were negative. Immunocytochemistry showed the majority of cells to contain insulin (Fig. 4) with a few staining positively for somatostatin. No glucagon-containing cells could be identified in multiple sections examined.
Examination of tissue from elsewhere in the excised pancreas revealed six discrete irregular endocrine cell nodules varying in size from 0 1 cm to 0-5 cm. The cellular morphology of all six was iden- tical to the main tumour. Three of the six were encapsulated. A further area of tumour was identified within the subcapsular sinus of a peripancreatic lymph node (Fig. 5) . All six nodules and the lymph node metastasis were strongly positive for glucagon (Fig. 6 ) and negative for both insulin and somatostatin.
The pancreatic islets in the intervening pancreas were irregular in outline and many were hyperplas- These clusters contained all three cell types apparently randomly arranged. The exocrine pancreatic tissue was unremarkable.
Discussion
The accepted classification of pancreatic endocrine tumours has been complicated by the demonstration of the mixed nature of many of these neoplasms.4 '°I t has been suggested that the name given to an individual tumour should depend on an appreciation of the clinical, biochemical, and immunocytochemical features of the case.5 However, it would seem worth retaining the terms insulinoma, glucagonoma, etc., in view of the recorded differences in biological behaviour.4 This case is presented as one of recurrent insulinoma syndrome complicated by the unexpected discovery of metastatic glucagonoma. Recurrent or multiple insulinomas6 are rare and most are associated with one of the multiple endocrine neoplasia syndromes.5 Malignancy as shown by metastasis, probably the only reliable criterion, is also a rare complication of insulinoma, approximately 5% in two large series.64 In contrast glucagonoma is much more often malignant, in more than 80% of cases in one series.5
The first tumour removed from this patient fulfilled the clinical and immunocytochemical criteria for diagnosis of insulinoma and its removal was followed by a long period of remission. The second tumour, although accompanied by a clinical insulinoma syndrome, showed marked positive staining for glucagon and was entirely negative for insulin. Resection was not accompanied by relief of symptoms and it would seem reasonable to regard this as a glucagonoma. The symptoms of excess glucagon secretion were probably masked by the presence of a further small insulinoma not detected at that time. This insulinoma presumably grew and constituted the main tumour removed at the time of pancreaticoduodenectomy. This third operation was again accompanied by relief of symptoms and the tumour showed positive staining for insulin and was negative for glucagon, and could therefore be confidently labelled an insulinoma. The metastasis found in a lymph node, staining strongly for glucagon only, was presumably metastatic from the glucagonoma previously removed and might be interpreted as evidence of the usual malignant behaviour of glucagonomas.
Despite the heterogeneity revealed by immunohistochemistry, all the tumour tissue examined showed identical staining reactions using conventional techniques. 
